# Semaglutide Research: How It Works, Trial Outcomes and Comparisons > Semaglutide research digest: how it works in the brain and pancreas, the STEP, SUSTAIN-6, SELECT and FLOW outcomes, semaglutide vs tirzepatide, and the oral-vs-injectable formulation science — all cited. ## Start here Semaglutide research is unusually deep — tens of thousands of people across weight, diabetes, heart, kidney and liver trials, plus animal studies that explain why it works. This page walks through the mechanism (what the drug does inside the body), the landmark trials and their numbers, how semaglutide stacks up against tirzepatide, and the formulation science that makes the oral tablet and the weekly shot behave differently. The one-paragraph version: semaglutide switches on GLP-1 receptors in the pancreas, the gut, and — crucially for weight — the brain's appetite centers. That lowers blood sugar, slows the stomach, and turns down hunger. The trials then measured what those effects add up to: big weight loss, fewer heart attacks and strokes, slower kidney decline. Every number below is tied to the study that produced it. Jargon is explained in plain words the first time it shows up. ## How does semaglutide work Semaglutide is a long-acting agonist (a switch-flipper) of the GLP-1 receptor. It mimics the natural incretin hormone GLP-1 but, because of its sturdier position-8 building block and its albumin-grabbing fatty-acid tail, it resists the DPP-4 enzyme and circulates for about a week instead of GLP-1's roughly two minutes. In the **pancreas**, switching on GLP-1 receptors boosts insulin only when blood sugar is high — that glucose-dependence is why semaglutide carries a low risk of dangerous lows on its own — and it quiets glucagon, a hormone that pushes blood sugar up. In the **gut**, it slows stomach emptying, so meals leave you feeling full longer. The weight effect is mostly in the **brain**. A rodent study showed semaglutide reaches appetite circuits directly — the brainstem area postrema (a region without a full blood-brain barrier), the hypothalamic arcuate nucleus, and the parabrachial nucleus — switching on satiety-promoting POMC/CART neurons and switching off hunger-driving NPY/AgRP neurons, which cut food intake and shifted food preference without lowering how many calories the animals burned [4]. A separate study mapped how GLP-1 medicines change those same NPY/AgRP and POMC neurons depending on the body's fuel state [13], and foundational work in mice had already pinpointed the arcuate nucleus as the spot where a related GLP-1 medicine drives weight loss [14]. The reward system plays a role too — a rodent study tied semaglutide's effect on alcohol intake to central reward pathways [12], which is the science behind all those anecdotes about wanting to drink less. ## Semaglutide peptide: the structure that makes it last As a **semaglutide peptide** at the chemistry level, semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing about 94% of its sequence (molecular weight ~4,113.6 Da; CAS 910463-68-2). Two backbone edits do the heavy lifting. At position 8, alanine is replaced by alpha-aminoisobutyric acid (Aib) to block DPP-4 — the enzyme that otherwise chops up natural GLP-1 in minutes. At position 34, lysine is swapped for arginine. The single remaining lysine at position 26 carries a long C18 fatty-diacid side chain through a small spacer; that lipid tail binds reversibly to serum albumin, shielding the peptide from kidney clearance and metabolism [5]. That albumin trick is the structural reason once-weekly dosing is possible — and it's identical in the tablet and the injection. The molecule is the same; only the delivery differs, which is the thread we follow on the [oral semaglutide](/oral) and [semaglutide half life](/half-life) pages. ## Semaglutide weight loss: the trial numbers **Semaglutide weight loss** has been measured in some of the largest obesity trials ever run. In STEP 1 (n=1,961 adults with overweight or obesity, no diabetes), the once-weekly 2.4 mg injection produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% on placebo — a treatment difference of about 12.4 percentage points [1]. The weight effect carries over into hard outcomes. In SELECT (n=17,604), in adults with established cardiovascular disease and overweight/obesity but no diabetes, the same 2.4 mg weekly dose cut the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20% (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. And the oral route delivers weight loss too: in the OASIS program, once-daily oral semaglutide at 50 mg produced clinically meaningful weight loss versus placebo in adults with overweight or obesity without diabetes [9]. One honest caveat the research carries: weight comes back after stopping (the STEP 1 extension saw a mean regain of about 11.6 percentage points within a year) [1], which is why the literature frames this as a chronic therapy rather than a cure. ## Blood sugar, heart and kidney outcomes Beyond weight, semaglutide has a stack of outcome trials most drugs never accumulate. **Blood sugar.** The PIONEER program established the oral tablet in type 2 diabetes: PIONEER 1 showed dose-dependent drops in HbA1c (a three-month blood-sugar average) and body weight with oral 3, 7 and 14 mg versus placebo [11], and PIONEER PLUS showed even larger improvements at higher oral doses of 25 and 50 mg [10]. **Heart, in diabetes.** SUSTAIN-6 (n=3,297, type 2 diabetes at high cardiovascular risk) was the first signal: the weekly 0.5 or 1.0 mg dose reduced major cardiovascular events (HR 0.74; 95% CI 0.58-0.95). The same trial flagged the retinopathy caution noted on the effects page (HR 1.76) [2]. **Kidney.** FLOW (n=3,533, type 2 diabetes with chronic kidney disease) tested the weekly 1.0 mg dose and cut major kidney events — kidney failure, a 50%+ drop in filtration rate, or kidney/cardiovascular death — by 24% (HR 0.76; 95% CI 0.66-0.88) [6]. A 2024 analysis found the cardiovascular benefit held consistently across kidney-disease severity [15]. ## Semaglutide vs tirzepatide The most-asked comparison gets a direct answer from one trial. In the head-to-head **semaglutide vs tirzepatide** study SURMOUNT-5 (n=751 adults with obesity), tirzepatide produced greater mean weight loss than semaglutide at 72 weeks: -20.2% versus -13.7%, a roughly 6.5-percentage-point advantage that was statistically significant (P<0.001) [7]. What to make of it: both results are large by any historical standard, and semaglutide's -13.7% in a head-to-head sits right alongside its STEP 1 result. Tirzepatide is a dual agonist — it hits a second gut-hormone receptor (GIP) in addition to GLP-1 — which is the leading explanation for the wider effect. The two drugs are different molecules, not two versions of one; this digest covers semaglutide and points to its own trial record rather than ranking the field. --- A bright, plain-English digest of the semaglutide record that reads the daily tablet and the once-weekly shot side by side — every trial number cited and the honest downsides kept in plain sight; no clinic behind the name, no prescription filled, and nothing here dosed or sold.